390 related articles for article (PubMed ID: 17151114)
21. Suppression of the LMP2A target gene, EGR-1, protects Hodgkin's lymphoma cells from entry to the EBV lytic cycle.
Vockerodt M; Wei W; Nagy E; Prouzova Z; Schrader A; Kube D; Rowe M; Woodman CB; Murray PG
J Pathol; 2013 Aug; 230(4):399-409. PubMed ID: 23592216
[TBL] [Abstract][Full Text] [Related]
22. Activated Notch1 modulates gene expression in B cells similarly to Epstein-Barr viral nuclear antigen 2.
Strobl LJ; Höfelmayr H; Marschall G; Brielmeier M; Bornkamm GW; Zimber-Strobl U
J Virol; 2000 Feb; 74(4):1727-35. PubMed ID: 10644343
[TBL] [Abstract][Full Text] [Related]
23. The distinction between Burkitt lymphoma and diffuse large B-Cell lymphoma with c-myc rearrangement.
Nakamura N; Nakamine H; Tamaru J; Nakamura S; Yoshino T; Ohshima K; Abe M
Mod Pathol; 2002 Jul; 15(7):771-6. PubMed ID: 12118116
[TBL] [Abstract][Full Text] [Related]
24. Epstein-Barr virus-encoded EBNA2 alters immune checkpoint PD-L1 expression by downregulating miR-34a in B-cell lymphomas.
Anastasiadou E; Stroopinsky D; Alimperti S; Jiao AL; Pyzer AR; Cippitelli C; Pepe G; Severa M; Rosenblatt J; Etna MP; Rieger S; Kempkes B; Coccia EM; Sui SJH; Chen CS; Uccini S; Avigan D; Faggioni A; Trivedi P; Slack FJ
Leukemia; 2019 Jan; 33(1):132-147. PubMed ID: 29946193
[TBL] [Abstract][Full Text] [Related]
25. c-myc activation renders proliferation of Epstein-Barr virus (EBV)-transformed cells independent of EBV nuclear antigen 2 and latent membrane protein 1.
Polack A; Hörtnagel K; Pajic A; Christoph B; Baier B; Falk M; Mautner J; Geltinger C; Bornkamm GW; Kempkes B
Proc Natl Acad Sci U S A; 1996 Sep; 93(19):10411-6. PubMed ID: 8816814
[TBL] [Abstract][Full Text] [Related]
26. Epstein-Barr virus-associated Burkitt lymphomagenesis selects for downregulation of the nuclear antigen EBNA2.
Kelly G; Bell A; Rickinson A
Nat Med; 2002 Oct; 8(10):1098-104. PubMed ID: 12219084
[TBL] [Abstract][Full Text] [Related]
27. T-cell leukemia 1 expression in nodal Epstein-Barr virus-negative diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma.
Gualco G; Weiss LM; Barber GN; Bacchi CE
Hum Pathol; 2010 Sep; 41(9):1238-44. PubMed ID: 20382409
[TBL] [Abstract][Full Text] [Related]
28. Interferon regulatory factor 7 regulates expression of Epstein-Barr virus latent membrane protein 1: a regulatory circuit.
Ning S; Hahn AM; Huye LE; Pagano JS
J Virol; 2003 Sep; 77(17):9359-68. PubMed ID: 12915551
[TBL] [Abstract][Full Text] [Related]
29. Nasal NK- and T-cell lymphomas share the same type of Epstein-Barr virus latency as nasopharyngeal carcinoma and Hodgkin's disease.
Chiang AK; Tao Q; Srivastava G; Ho FC
Int J Cancer; 1996 Nov; 68(3):285-90. PubMed ID: 8903467
[TBL] [Abstract][Full Text] [Related]
30. Enhanced susceptibility of B lymphoma cells to measles virus by Epstein-Barr virus type III latency that upregulates CD150/signaling lymphocytic activation molecule.
Takeda S; Kanbayashi D; Kurata T; Yoshiyama H; Komano J
Cancer Sci; 2014 Feb; 105(2):211-8. PubMed ID: 24238277
[TBL] [Abstract][Full Text] [Related]
31. BCL-6 gene product, a 92- to 98-kD nuclear phosphoprotein, is highly expressed in germinal center B cells and their neoplastic counterparts.
Onizuka T; Moriyama M; Yamochi T; Kuroda T; Kazama A; Kanazawa N; Sato K; Kato T; Ota H; Mori S
Blood; 1995 Jul; 86(1):28-37. PubMed ID: 7795234
[TBL] [Abstract][Full Text] [Related]
32. Epstein-Barr virus-latent gene expression and tumor cell phenotype in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma. Correlation of lymphoma phenotype with three distinct patterns of viral latency.
Hamilton-Dutoit SJ; Rea D; Raphael M; Sandvej K; Delecluse HJ; Gisselbrecht C; Marelle L; van Krieken HJ; Pallesen G
Am J Pathol; 1993 Oct; 143(4):1072-85. PubMed ID: 8214003
[TBL] [Abstract][Full Text] [Related]
33. Primary mediastinal B-cell lymphoma: hypermutation of the BCL6 gene targets motifs different from those in diffuse large B-cell and follicular lymphomas.
Malpeli G; Barbi S; Moore PS; Scardoni M; Chilosi M; Scarpa A; Menestrina F
Haematologica; 2004 Sep; 89(9):1091-9. PubMed ID: 15377470
[TBL] [Abstract][Full Text] [Related]
34. Epstein-Barr virus nuclear antigen 2 (EBNA2) gene deletion is consistently linked with EBNA3A, -3B, and -3C expression in Burkitt's lymphoma cells and with increased resistance to apoptosis.
Kelly GL; Milner AE; Tierney RJ; Croom-Carter DS; Altmann M; Hammerschmidt W; Bell AI; Rickinson AB
J Virol; 2005 Aug; 79(16):10709-17. PubMed ID: 16051863
[TBL] [Abstract][Full Text] [Related]
35. Deregulated BCL6 expression recapitulates the pathogenesis of human diffuse large B cell lymphomas in mice.
Cattoretti G; Pasqualucci L; Ballon G; Tam W; Nandula SV; Shen Q; Mo T; Murty VV; Dalla-Favera R
Cancer Cell; 2005 May; 7(5):445-55. PubMed ID: 15894265
[TBL] [Abstract][Full Text] [Related]
36. Epstein-Barr virus contributes to the malignant phenotype and to apoptosis resistance in Burkitt's lymphoma cell line Akata.
Komano J; Sugiura M; Takada K
J Virol; 1998 Nov; 72(11):9150-6. PubMed ID: 9765461
[TBL] [Abstract][Full Text] [Related]
37. Response to cAMP levels of the Epstein-Barr virus EBNA2-inducible LMP1 oncogene and EBNA2 inhibition of a PP1-like activity.
Fåhraeus R; Palmqvist L; Nerdstedt A; Farzad S; Rymo L; Laín S
EMBO J; 1994 Dec; 13(24):6041-51. PubMed ID: 7813442
[TBL] [Abstract][Full Text] [Related]
38. Transient expression of the Epstein-Barr virus LMP1 gene in B-cell chronic lymphocytic leukemia cells, T cells, and hematopoietic cell lines: cell-type-independent-induction of CD23, CD21, and ICAM-1.
Peng M; Lundgren E
Leukemia; 1993 Jan; 7(1):104-12. PubMed ID: 8093369
[TBL] [Abstract][Full Text] [Related]
39. CpG methylation of the major Epstein-Barr virus latency promoter in Burkitt's lymphoma and Hodgkin's disease.
Robertson KD; Manns A; Swinnen LJ; Zong JC; Gulley ML; Ambinder RF
Blood; 1996 Oct; 88(8):3129-36. PubMed ID: 8874213
[TBL] [Abstract][Full Text] [Related]
40. Differences in EBNA2 and LMP-1 carboxy terminal region sequences of Epstein-Barr virus type A between the tumors in a multiple cancer patient.
Higa M; Kinjo T; Miyagi J; Sakumoto N; Iwamasa T; Kishaba M; Sunakawa H
Pathol Res Pract; 2001; 197(6):401-9. PubMed ID: 11432667
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
